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Despite reported success in reducing severe disease-associated morbidities in endemic 
countries, praziquantel (PZQ) alone has failed to control and eliminate schistosomiasis, partly 
due to its poor efficacy against immature/juvenile worms. Artemisinin derivatives are 
efficacious against juvenile schistosomes. Therefore, combining PZQ with 
Dihydroartemisinin-piperaquine (DHP) would complement and potentially add to the killing 
effect of both mature and immature (juvenile) stages of the parasite to improve cure rates and 
hence hasten control and elimination of the disease (multi-factorial) and delay development 
of resistance against PZQ. This PhD thesis aimed to assess the efficacy and safety of PZQ 
and DHP combination therapy for the treatment and control of intestinal schistosomiasis 
among school children in Busega district, North-western Tanzania. 
First, a baseline survey was conducted to assess the prevalence and correlates of intestinal 
schistosomiasis infection among 830 school-aged children in North-western Tanzania (paper 
I). A high (90.6%) prevalence of intestinal schistosomiasis infection was observed among 
school children despite several rounds of mass PZQ treatments in the study area. The 
prevalence of malaria was found to be very low (<2%). Anaemia (24.6%) and undernutrition 
such as stunting 29.0% and wasting 11.3% continued to be a major burden among this age 
group. Being male, having loose stool, and being stunted were the factors found to be 
significantly associated with high egg counts among those infected. Only lower age (≤ 12 
years) was significantly associated with intestinal schistosomiasis infection and not malaria, 
anaemia or undernutrition status.  
In paper II, a prospective surveillance study was conducted among 341 infected school 
children to assess the efficacy and safety of single-dose PZQ for treatment of Schistosoma 
mansoni infection. Follow-up was done at three weeks post-treatment according to WHO 
guidelines. We observed that PZQ given as a single-dose at 40 mg/kg body weight is still 
efficacious and safe for the treatment of Schistosoma mansoni infection. The overall cure and 
egg reduction rates were 81.2% and 95.0%, respectively. The incidence of adverse events was 
28.5%, with abdominal pain being the most common. Post-treatment abdominal pain and 
vomiting were significantly associated with pre-treatment infection intensity and anaemia, 
respectively.  
In paper III, a randomized, open-label, non-inferiority clinical trial was conducted to assess 
the efficacy and safety of PZQ and DHP combination (n = 298) versus PZQ alone (n = 341). 
This study has found that PZQ and DHP combination therapy is equally safe and more 
efficacious than PZQ alone for the treatment of intestinal schistosomiasis. At three weeks post-
treatment, cure rates were significantly higher in combination therapy (88.3%) than PZQ alone 
(81.2%) (p = 0.01). At eight weeks post-treatment, there was a significant drop in the cure rates 
in PZQ alone to 63.9% compared to 81.9% in the PZQ and DHP combination therapy (p < 
0.0001). Egg reduction rates at eight weeks post-treatment were significantly higher in the PZQ 
and DHP combination therapy (93.6%) than 87.9% in the PZQ alone group (p = 0.01). Overall, 
30.8% of the study participants experienced mild and transient adverse events, abdominal pain 
being the most common adverse event. There was no significant difference in the overall 
incidence of adverse events between treatment groups.  
In paper IV, a two-arm pharmacokinetic study was conducted among 64 treated children to 
assess drug-drug interaction and its clinical significance between PZQ and DHP. This study 
has found that the systemic exposure of PZQ and its enantiomers is increased following 
coadministration with DHP. The geometric means of AUCs and Cmax of both total PZQ, R-
PZQ and S-PZQ were significantly higher among those children treated with PZQ and DHP 
combination (n = 32) than those who were treated by PZQ alone (n = 32). The 90% confidence 
interval of the geometric mean ratios of both total PZQ, R-PZQ and S-PZQ were outside the 
acceptable bioequivalent interval of 0.80, 1.25, indicating higher systemic exposure among 
those who were treated with PZQ and DHP combination therapy. The increased PZQ 
bioavailability in the PZQ and DHP combination is an additional mechanism to enhance the 
cure rates apart from the killing of both mature and immature stages of the parasite. 
In paper V, a pharmacogenetics study was conducted among 340 children to assess the effect 
of genetic variations in CYP450 on plasma drug concentrations, treatment efficacy and adverse 
events.. We observed a significant association between CYP2C19 genotype and PZQ 
concentration, and its metabolic ratio (trans-4-OH-PZQ/PZQ). PZQ concentration was 
significantly higher among children carrying CYP2C19 (*2, *3) defective alleles than the wild 
type (CYP2C19 *1/*1) and CYP2C19 *17 carriers (ultra-rapid metabolizers) (p = 0.04). The 
metabolic ratio was significantly higher among CYP2C19 *17 carriers than CYP2C19 (*2, *3) 
carriers (p = 0.01). There was no significant effect of CYP3A4, CYP2C19 and CYP2C9 
genotypes on schistosomiasis treatment efficacy and adverse events (p > 0.05). However, a 
border line association between CYP3A5 genotype and adverse events was observed (p = 
0.048). On multivariate logistic regression analysis, baseline infection intensity was found to 
be the only significant predictor of adverse events following PZQ treatment. 
In conclusion, PZQ and DHP combination therapy is equally safe and more efficacious than 
PZQ alone for treatment of schistosomiasis. The increased systemic PZQ exposure following 
a co-administration of DHP, yet without affecting overall safety, is an additional mechanism 
to the observed higher cure rate among children treated with PZQ and DHP combination 
therapy. These findings call for policy makers and other stakeholders to consider the use of 
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1.1 THE BURDEN OF NEGLECTED TROPICAL DISEASES 
Neglected Tropical Diseases (NTDs) are still a public health challenge, especially among 
children in Sub-Saharan Africa (SSA) [1-3]. NTDs are a group of poverty-related diseases that 
prevail in tropical and sub-tropical regions [4].  Currently, the World Health Organization 
(WHO) recognizes a total of 20 NTDs that have different causative agents, including protozoa, 
helminths, bacteria, and viruses. NTDs have a major negative socio-economic impact among 
families and communities, mostly in low and middle-income countries [4].  Thus, the SSA 
region remains one of the most affected areas [1, 3, 4].  
NTDs are associated with disabilities, poor growth, and cognitive performance, prevent 
children from attending school, thus affecting their future socio-economic life [5].  On the other 
hand, infected older populations become less involved in economic activities and hence 
become less productive to their families and community [1, 6].  About 534,000 deaths and 
more than 57 million Disability-Adjusted Life Years (DALYs) are attributed to NTDs annually 
[2]. The global burden of DALYs due to NTDs has been reported to be greater than that of 
malaria (46.5 DALYs) and tuberculosis (34.7 DALYs) [7]. Furthermore, NTDs also affect the 
human development index’s (HDI) key components, such as living standards, quality education 
and years of schooling, and years of life lived with good health [8].  
The healthy and socio-economic consequences of NTDs further fuel the burden of poverty to 
the families, communities, countries and SSA region. NTDs have also been linked to the delay 
in the achievement of sustainable development goals (SDGs), e.g. SDG1 (no poverty), SDG3 
(good health for all), and SDG4 (quality education) [8, 9].  Earlier studies have shown that 
treatment and control of NTDs have been associated with a direct impact on the efforts towards 
achievement of the SDGs [10]. The current global agenda is to eliminate NTDs by the year 
2030. To achieve this milestone, further research on treatment optimization and control 
strategies is needed. Schistosomiasis is among the NTDs targeted for control (heavy infection 
< 5%) and elimination (heavy infection < 1%) as a public health challenge globally by the year 
2025 [11, 12].  
1.2 THE GLOBAL BURDEN OF SCHISTOSOMIASIS 
Schistosomiasis is a poverty-related NTD caused by a parasite blood fluke or trematode of the 
genus Schistosoma [13]. Several Schistosoma species exist; however, only three major species 
infect humans namely Schistosoma haematobium, Schistosoma mansoni and Schistosoma 
japonicum [13]. Other species are Schistosoma mekongi and Schistosoma intercalatum that 
infect other mammals [13].  In many areas of the SSA, Schistosoma haematobium and 
Schistosoma mansoni are the predominant species and cause significant morbidity and 
mortality, making them of public health importance in the region [1, 13].  
Schistosomiasis is endemic in 78 countries worldwide [14]. Globally, more than 250 million 
people are infected, and about 800 million people are at risk of the disease [14, 15].  More than 
90% of the reported disease global burden is contributed by cases from SSA, where it causes 
about 150,000 - 280,000 deaths annually [2, 15]. Schistosomiasis is estimated to cause up to 
3.31 million DALYs annually [2]. According to the WHO, by 2017, approximately 99 million 
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people (81.1 million being school-aged children) received schistosomiasis treatment 
worldwide [16]. Schistosomiasis is a treatable and preventable disease but, if not treated, may 
cause renal failure, hydronephrosis, upper gastrointestinal bleeding as a result of portal 
hypertension, and cancer due to chronic inflammation resulting from migrating parasites eggs 
in body tissues [1]. These health consequences further increase the burden and cost in the health 
care system in the affected countries.  
Apart from its morbidities, schistosomiasis has been associated with an increased risk of 
Human Immunodeficiency Virus (HIV) transmission and progression [17-19]. Additionally, 
studies have also shown that Schistosoma mansoni infection increases susceptibility to malaria 
by changing the balance of T-helper cells 1 and 2 immune responses affecting the 
immunological protection of malaria [19-22]. In addition to that, the morbidity and severity of 
parasitic infections, including malaria, increases when in co-infection with schistosomiasis [19, 
23]. Schistosomiasis has also been linked to poor pregnancy outcomes due to anemias in 
pregnancy, which may eventually cause maternal mortality and/or low birth weight (LBW) 
[24, 25].  
Though there is still a debate on the relationship between schistosomiasis and anaemia, some 
studies have indicated a significant association between schistosomiasis (i.e. Schistosoma 
haematobium) and anaemia among children [26]. Despite the lack of association between 
schistosomiasis and anaemia in most studies, a high burden of anaemia was reported among 
those infected with schistosomiasis [27-30]. Additionally, schistosomiasis has also been 
associated with undernutrition (stunting and wasting) [31, 32], but also the presence of 
undernutrition (e.g. stunting) is associated with high eggs count among those infected [29]. 
Studies conducted to assess the efficacy of Bacillus Calmette–Guérin (BCG) vaccination for 
tuberculosis have reported a reduced protective effect among those infected with Schistosoma 
mansoni, particularly in heavy infections [33]. All these negative outcomes of schistosomiasis 
can significantly be reduced if the disease is controlled or eliminated. Therefore, there is a need 
to continuously assess the prevalence of schistosomiasis in endemic countries to inform the 
responsible authorities such as the national NTDs control and elimination programs for 
appropriate actions. 
1.3 THE EPIDEMIOLOGY OF SCHISTOSOMIASIS IN TANZANIA 
The first report of schistosomiasis in Tanzania was reported on intestinal schistosomiasis back 
in early 1895 [34]. Since then, the distribution and epidemiology of both intestinal 
schistosomiasis and urogenital schistosomiasis have been reported all over the country, with 
the level of endemicity and prevalence varying from region to region [35].   The distribution of 
schistosomiasis is mainly influenced by the availability and distribution of an intermediate host 
of the parasite (i.e. snails) [35]. Schistosoma haematobium was reported to be endemic 
throughout the country, with the Eastern and South-Eastern coasts of the country being highly 
affected [36, 37]. On the other hand, Schistosoma mansoni was reported to be highly prevalent 
in the North-western part of the country surrounding Lake Victoria [38, 39]. While in Zanzibar 
Islands (Unguja and Pemba), Schistosoma haematobium is the only endemic species [40]. The 
prevalence of schistosomiasis has been reported to increase over the years in the country, with 
an increase in the national population size [35]. In 1979-1980, about 28.3% and 23.2% of the 
Tanzania mainland population were infected with urogenital and intestinal schistosomiasis, 
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respectively [41]. In the 1990s, the prevalence of schistosomiasis was reported to increase to 
about 51.5% [42]. In 2009, about 19 million people of the 43.5 million estimated populations 
were infected with schistosomiasis [3].  
To date, despite ongoing control interventions, schistosomiasis is still endemic throughout the 
country [43] and highly prevalent around the Lake Victoria Zone, where a prevalence of up to 
100% has been reported in some areas (Figure 1) [35]. A study conducted in 2016 to assess the 
progress of schistosomiasis control globally has reported Tanzania among the countries not yet 
to achieve schistosomiasis control and elimination (Figure 2) [43]. Additionally, studies 
conducted within the country in 2016 and 2017 around the Lake Zone have reported an 
alarmingly high prevalence of intestinal schistosomiasis of > 80% among school children [27, 
28]. On the other hand, currently, there is evidence of a high prevalence of schistosomiasis (> 
45%) among pre-school children in Tanzania [44]. The pre-school children were not part of 
mass praziquantel (PZQ) treatment campaigns in the country and, therefore, served as a 
reservoir of infection for many years.  
Though schistosomiasis has not been adequately studied among pregnant women, a high 
prevalence of more than 60% has been reported among pregnant women in Tanzania [25]. This 
overall burden of schistosomiasis in different age groups makes Tanzania the second most 
affected country by the disease next to Nigeria among the African countries [45]. Therefore, 
there is a need to continue monitoring the prevalence of schistosomiasis in the country across 
all age groups. Assessment of disease prevalence is the only way to inform the national NTDs 
control programs on the progress of the ongoing interventions [46].  
 
 
Figure 1: Map of Tanzania showing the distribution of both Schistosoma mansoni and 





Figure 2: A global map showing the outcome of schistosomiasis control and elimination as of 
2016. Tanzania is among the SSA countries not yet succeeded in achieving schistosomiasis 
control. Source: Sokolow SH et al., 2016 [43]. 
1.4 LIFE CYCLE AND TRANSMISSION OF SCHISTOSOMIASIS 
Schistosomes have two different hosts and two developmental stages in their life cycle (mature 
and immature stages) [47]. The human being is the definitive host and acquires the infection 
through contaminated freshwater bodies (lakes, dams, ponds, and rivers) with an infective 
larvae stage of the parasite called cercariae [47]. The cercariae penetrate human skin and 
develop into immature or juvenile worms called schistosomula [47].  This stage of the parasite 
is less affected by PZQ, the drug currently used for the treatment of schistosomiasis [48].  
The immature schistosomula are then carried in the blood to the portal vein of the liver, where 
they develop into mature adult worms and this process takes about 4 to 6 weeks [1, 47]. After 
that, a pair of matured female and male adults migrates against venous blood from the liver 
(portal vein) to the perivesical venous plexus of the bladder (Schistosoma haematobium) and 
venous plexus of mesenteries of the bowel and portal veins (Schistosoma mansoni) [47].  
Within these venules, female parasites start to lay up to several hundred eggs per day for several 
years. Adult schistosome parasites can survive for 3 to 10 years, while eggs can survive for 1 
to 2 weeks [47].  
The eggs penetrate the tissue causing intensive inflammation and organ damage, while other 
eggs reach the lumen of the bladder (Schistosoma haematobium) or colon (Schistosoma 
mansoni) excreted in either urine or stool, respectively. The excreted eggs hatch in freshwater 
to release miracidia which penetrate the freshwater snails (intermediate host), multiplying by 
asexual reproduction to form cercariae, the infective stage of the parasite. This process takes 
about 4 to 6 weeks [47]. Then the infective cercariae are released into water to search for a 
definitive human host to complete the cycle (Figure 3). Intermediate snail hosts of the Bulinus 
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species are responsible for transmission of Schistosoma haematobium while Biomphalaria 
species are responsible for transmission of Schistosoma mansoni [49]. 
 
Figure 3: Life cycle of Schistosoma. Source: Centers for Disease Control and Prevention 
(CDC): Source: http://www.cdc.gov/dpdx/schistosomiasis/.  
1.5 CLINICAL MANIFESTATIONS OF SCHISTOSOMIASIS 
Most infected people in endemic countries are asymptomatic. In general, schistosomiasis 
causes disabilities more than it kills. Most morbidities associated with schistosomiasis result 
from the body’s immune reaction to the migrating parasite eggs [50]. Schistosomiasis has three 
main clinical phases, whereby the first phase is characterized by dermatitis and is caused by 
the penetrating cercariae [51]. The second phase is marked by fever (Katayama fever) and other 
constitutional complaints, e.g., headache, fatigue, cough due to migrating schistosomula and 
eggs  [52].  The last phase results in chronic inflammation and tissue damage which is caused 
by parasite eggs trapped into host tissue [53].  Table 1 summarizes the clinical phases and 






Table 1. Clinical phases and symptoms of schistosomiasis  
Clinical phase Symptoms 
Immediate Acute, pruritic, maculopapular eruption at site of cercarial skin penetration 
within 1 day following exposure 
  
Acute Systematic hypersensitivity reaction against migrating schistosomula, fever, 
fatigue, myalgia, malaise, nonproductive cough, eosinophilia, patchy 
infiltrates, weight loss, dyspnea, diarrhea, diffuse abdominal pain, toxemia, 
hepatosplenomegaly, widespread rash 
Chronic Affects gastrointestinal and urogenital tracts, leading to hepatosplenic and 
pelvic organ diseases, portal and pulmonary hypertension, abdominal ascites, 
upper gastrointestinal varices and hemorrhage, female genital 
schistosomiasis, infertility, increased risk of HIV-1 transmission, and 
squamous cell carcinoma of the bladder 
Source ‘Vale N et al., 2017 [54]. 
Classic symptoms of intestinal schistosomiasis include abdominal pain, diarrhoea or bloody 
diarrhoea [53]. Enlargement of the liver (hepatomegaly) occurs mostly in the advanced stage 
of the disease [50]. Hepatomegaly is frequently accompanied by fluid in the peritoneal cavity 
and raised blood pressure in the portal veins (portal hypertension), which may further cause 
upper gastrointestinal bleeding as a complication [50]. Hepatomegaly is also associated with 
enlargement of the spleen (splenomegaly) in advanced cases [50]. If not treated, intestinal 
schistosomiasis associated with health consequences, including anaemia, growth retardation 
(stunting and wasting), decreased physical fitness, and poor cognitive development. These 
health consequences can negatively impact children’s ability to learn [1]. Therefore, infected 
children will not be able to achieve life potentials, particularly in endemic countries with 
extreme poverty.  
For urogenital schistosomiasis, the classic clinical sign is blood in the urine (haematuria) [50]. 
Kidney damage and urinary bladder fibrosis may occur in the advanced stages of the disease 
[53]. The latter may progress to urinary bladder cancer in some patients [50]. Urogenital 
schistosomiasis can also affect reproductive organs and may cause infertility in both sexes [55]. 
Therefore, it is important to continuously assess schistosomiasis-associated co-morbidities, 
including anaemia and nutritional deficiencies in future studies that will be conducted to assess 
the prevalence of schistosomiasis. However, all health consequences mentioned above 
associated with schistosomiasis can be prevented by administering preventive chemotherapy 
to people at risk in endemic areas such as school-aged children and fishermen. 
1.6 DIAGNOSIS OF SCHISTOSOMIASIS 
The current strategy for schistosomiasis control and elimination is preventive chemotherapy by 
mass drug administration (MDA) using PZQ. The assumption is that in such settings, all or 
most people are infected with the disease. However, in a situations where the diagnosis is 
important, e.g. individual case management in clinics, in epidemiological studies or in studies 
conducted to assess drug efficacy, diagnosis of schistosomiasis can be made by microscopic 
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examination of schistosome eggs in stool or urine samples using the Kato-Katz method 
(intestinal schistosomiasis) or urine filtration method (urinary schistosomiasis). DNA 
detection, antigen tests such as the point of care circulating cathodic or anodic antigen (POC 
CCA/CAA) and molecular diagnostics such as the loop-mediated isothermal amplification 
(LAMP) or polymerase chain reaction (PCR) can also be used [53].  
The non-microscopy-based tests are more sensitive in diagnosing schistosomiasis [56, 57], the 
WHO still recommends microscopic examination as a gold standard method for diagnosis of 
schistosomiasis, especially in resource-limited settings [12, 58]. Multiple stool samples 
collected on two or three consecutive days have been reported to increase the sensitivity of the 
Kato Katz method, especially in clinical trials; however, in routine disease surveillance, this 
approach may be costly [53]. In endemic countries with limited resources, the diagnostic test’s 
choice greatly depends on its simplicity, accuracy, less laborious and, most importantly, cost 
[12, 59]. At the disease elimination stage or in very low infection intensity, it is very important 
to have more sensitive diagnostic tools for disease surveillance [56, 60]. Although the more 
sensitive tests are expensive but at the elimination stage, the cost has been reported to be 
outweighed by the long-term benefits [11, 58]. Therefore, affected countries working towards 
controlling and eliminating schistosomiasis must be prepared for this cost in advance.  
1.7 SCHISTOSOMIASIS TREATMENT, PREVENTION AND CONTROL 
STRATEGIES 
The WHO promotes five main public health interventions against schistosomiasis [12, 61]. 
These interventions include preventive chemotherapy, snail control and access to safe and clean 
drinking water, basic sanitation and hygiene, and health education. However, due to financial 
difficulties in most endemic countries, including Tanzania, preventive chemotherapy targeting 
school-aged children is the main strategy for treating, preventing, and controlling 
schistosomiasis [62]. This strategy has been long implemented despite the reported evidence 
that snail control gives the best outcomes in terms of long-term schistosomiasis prevalence 
reduction and possible elimination [14, 43]. Periodic mass PZQ treatment given to infected and 
at-risk populations is the WHO recommendation for treatment, prevention and control of 
schistosomiasis. In Tanzania, mass PZQ treatment targeting school-aged children was started 
in the year 2004/2005 [63]. 
1.7.1 Preventive chemotherapy and its goals in schistosomiasis treatment 
and control 
Preventive chemotherapy is a key strategy recommended by the WHO to treat, prevent and 
control helminths infections, including schistosomiasis [62]. It is the most preferred strategy 
due to its logistic feasibility during implementation and cost-effectiveness. Preventive 
chemotherapy involves large-scale mass antihelminthic drug administration to communities at 
risk of the disease in endemic countries. In schistosomiasis, preventive chemotherapy with the 
large-scale use of PZQ is the WHO-recommended strategy. Since 1984, PZQ has been reported 
as a safe, well-tolerated, and efficacious drug against all Schistosoma species [61]. In most 
endemic countries, including Tanzania, preventive chemotherapy is mainly focused on school-
aged children. The frequency of PZQ preventive chemotherapy depends on the prevalence of 
the disease [64]. Table 2 presents the frequency of PZQ MDA as recommended by the WHO.  
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Table 2. The WHO recommended PZQ preventive chemotherapy based on thresholds of the 
prevalence of schistosomiasis infection 
Category Baseline prevalence among 
school-age children 
Action to be taken 
High-risk 
community 
50% by parasitological 
methods (intestinal and 
urogenital schistosomiasis) or 
30% by questionnaire for 
history of haematuria 
Treat all school-age 
children (enrolled and 
not enrolled) once a 
year 
Also treat adults 
considered to be a risk 
(from special groups to 
entire communities living 
in endemic areas) 
Moderate-risk 
community 
10% but < 50% by 
parasitological methods 
(intestinal and urogenital 
schistosomiasis) or <30% by 
questionnaire for history of 
haematuria 
Treat all school-age 
children (enrolled and 
not enrolled) once 
every 2 years 
Also treat adults 
considered to be at 
risk (special groups only) 
Low-risk 
community 
<10% by parasitological 
methods (intestinal and 
urogenital schistosomiasis) 
Treat all school-age 
children (enrolled and 
not enrolled) twice 
during their primary 
schooling age (e.g. 
once on entry and 
once on exit) 
Praziquantel should be 
available in dispensaries 
and clinics for treatment 
of suspected cases 
Source: Schistosomiasis: progress report 2001 - 2011, strategic plan 2012 – 2020 [12]  
The initial aim of preventive chemotherapy was morbidity control to reduce severe morbidities 
associated with the disease [64]. After several years of mass PZQ administration and decline 
in severe morbidity associated with the disease [65], in 2012, WHO recommended its member 
states to think beyond reducing severe morbidities to elimination [11, 66]. Despite this effort 
from the WHO, PZQ alone treatment seems not sufficient enough to control and eliminate 
schistosomiasis [35]. Several reasons have been reported for the continued high 
schistosomiasis transmission and prevalence, including lack of vaccine [67], lack of safe and 
clean water [68], poor sanitation and hygiene [69], and treatment coverage that excluded other 
key populations such as pre-school children.  
More importantly, with preventive chemotherapy itself, the inability of PZQ to act against 
immature or juvenile worms (schistosomula) has been reported as one of the reasons 
responsible for continued high schistosomiasis transmission and prevalence [48]. In addition, 
a threat of PZQ resistance has been reported in field studies in SSA [70]. Therefore, there is a 
need to continue monitoring the efficacy and safety of PZQ for early detection of resistance 
but also the need for treatment optimization research to find a better alternative treatment to 
PZQ. Due to the alarming threat of PZQ resistance, the new alternative treatment should not 
only improve schistosomiasis treatment efficacy but also reduce or delay the development of 
resistance against PZQ.  
 
 9 
1.7.2 Efficacy and safety of praziquantel for treatment of schistosomiasis 
Following several years of PZQ use in schistosomiasis endemic countries, low cure rates, and 
drug tolerance/resistance have been reported in field studies conducted in SSA [70]. Cure rates 
following single-dose PZQ treatment at a dose of 40 mg/kg body weight have been reported to 
range between 42 and 79% for Schistosoma mansoni and between 37 and 93% for Schistosoma 
haematobium in school-aged children [71]. In some studies, a cure rate as low as 18% has been 
reported in Senegal, raising the concern about the current efficacy of PZQ, particularly against 
Schistosoma mansoni infection [70].  These reports indicate the need for regular monitoring of 
the efficacy of PZQ for the early detection of drug resistance. So far, there is no confirmed or 
documented report of PZQ resistance [72]. The fact that there is no alternative drug for the 
treatment and control of this poverty-related disease makes close monitoring of its performance 
vital.  
In Tanzania, despite 100% geographical coverage, repeated cycles of targeted MDA focusing 
on school-aged children, and the reported national treatment coverage of > 90% [73], the 
prevalence of schistosomiasis remains high, especially with Schistosoma mansoni infection 
around the Lake Victoria Zone [27-29]. PZQ has been reported to have high efficacy against 
Schistosoma haematobium [74] than Schistosoma mansoni infection [75]. Therefore, 
monitoring PZQ efficacy against Schistosoma mansoni may need to be prioritized in endemic 
areas where both Schistosoma species are endemic, like in Tanzania [35]. Also, the WHO 
recommends assessing drug efficacy if the prevalence and intensity of infection remain high 
despite preventive chemotherapy [46], and this has been the case for Schistosoma mansoni 
infection around the Lake Victoria Zone in Tanzania [27-29, 35]. Data regarding the current 
efficacy of PZQ MDA against Schistosoma mansoni infection remains scarce in the country. 
 PZQ is a chiral compound and racemic mixture of R-praziquantel (R-PZQ) and S-praziquantel 
(S-PZQ) enantiomers. Recent studies have indicated that R-PZQ is pharmacologically active 
and contributing to the antischistosomal activity of PZQ [76-78]. S-PZQ has been reported to 
increase the size of the PZQ tablet and responsible for the bitter taste [79]. Studies to investigate 
the use of monoenantiomeric R-PZQ formulation for the treatment of schistosomiasis 
especially in children are in pipeline.  
Like any other drug, PZQ use has been associated with adverse events in some populations 
[80]. The adverse events related to PZQ have been broadly categorized as (i) dermatological 
(e.g. itching, skin rashes, urticaria), (ii) gastrointestinal (e.g. abdominal pain, nausea, vomiting, 
diarrhoea), (iii) neurological (e.g. muscle pain, headache, dizziness, drowsiness, fainting), and 
lastly allergic symptoms [80]. Most of these PZQ associated adverse events were reported to 
be mild and resolve within 24 hours of drug intake [80, 81]. PZQ related adverse events have 
also been reported to be associated with pre-treatment infection intensities, age, and other 
medical conditions such as poor nutritional status and anaemia [80, 81]. Heavily infected 
patients were reported to encounter significantly more adverse events than those with light to 
moderate infection [80, 81]. Since the treatment-associated adverse events are associated with 
pre-treatment infection intensity, there is a need for regular monitoring of the safety of PZQ in 
MDA.  
The WHO recommends ensuring safety in large-scale MDA programs involving the use of 
antihelminthic drugs [82]. Currently, there are large-scale donations of antihelminthic drugs, 
 
10 
including PZQ, from pharmaceutical companies and global health organizations under the 
influence of the WHO for the treatment and control of NTDs worldwide. Although this scale-
up in PZQ donations is necessary, it also calls for regular monitoring of the drug efficacy and 
safety [83]. 
1.8 ALTERNATIVES TREATMENT STRATEGIES TO SINGLE-DOSE 
PRAZIQUANTEL  
To date, there is no approved vaccine in the market for schistosomiasis prevention, although 
potential candidates are on clinical trials [48, 67]. Likewise, there are no new antischistosomal 
drugs approved for the treatment and control of schistosomiasis. With the reported threat of 
PZQ resistance, there is a pressing need for a new treatment alternative. Optimization of 
available drugs in the market remains the only option in the era of schistosomiasis control and 
elimination worldwide [84]. Several treatment strategies have been tested in an attempt to 
optimize schistosomiasis treatment outcomes, including the use of higher PZQ doses [85, 86], 
repeated PZQ doses [75, 87-89], and combination chemotherapy [90]. However, each strategy 
has shown its weaknesses or limitations, as detailed below. Hence the need for exploring other 
treatment options [56].  
1.8.1 Higher praziquantel doses 
Higher PZQ doses (> 40mg/kg body weight) have been tested and demonstrated contradicting 
findings regarding egg clearance/efficacy. They have shown improved cure rates in some 
studies [86] while no beneficial effects in other studies [85]. Despite success in some studies, 
higher PZQ doses have been associated with significantly more treatment-associated adverse 
events than the standard dose of 40mg/kg body weight [86]. Therefore, this strategy was not 
adopted for use due to safety concerns. Indeed, with the current wide implementation of 
targeted large-scale preventive chemotherapy for the control and elimination of NTDs, the 
safety of administered drugs to the affected populations is the WHO recommendation [82] and 
critically important for treatment coverage and MDA compliance [56]. 
1.8.2 Repeated praziquantel treatment strategy 
The utility of repeated PZQ doses in the space of 3-6 weeks has been investigated in endemic 
countries to kill the left behind parasites that were immature during the first round or dose of 
PZQ MDA [88]. This way of administering PZQ has shown success in improving cure rates, 
particularly in high disease transmission areas [87, 88]. Although there is still ongoing debate 
regarding the usefulness of repeated PZQ doses versus cost and the risk of accelerating PZQ 
resistance, the use of this strategy in high schistosomiasis transmission areas where a single 
annual PZQ dose is obviously not adequate cannot be underestimated.  
However, repeated PZQ doses strategy will definitely increase PZQ use, and previous studies 
have reported that increased PZQ MDA rounds have been linked to low cure rates and may 
also increase the risk of PZQ resistance [91]. Furthermore, repeated PZQ doses strategy has 
potential for poor implementation, especially that schistosomiasis affects developing countries 
with limited resources. A survey of experts towards NTDs eliminations has indicated a lack of 
resources as a major challenge in schistosomiasis control and elimination in endemic countries 
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[92]. Therefore, repeated PZQ doses strategy, despite its reported success in improving the cure 
rates, may not be cost-effective in endemic countries with limited resources. 
1.8.3 Combination chemotherapy for schistosomiasis 
Like in other infectious diseases such as HIV, tuberculosis and malaria, combination therapy 
remains the only hope and feasible strategy to optimize schistosomiasis treatment outcomes 
[90]. In fact, like in other infectious diseases, the combination therapy strategy will not only 
improve treatment outcomes but also will reduce or delay the development of resistance against 
PZQ provided that drugs have independent mechanisms of action and/or act on a different 
developmental stage of the parasite [90, 93-95].   
1.8.3.1 PZQ and Oxamniquine Combination therapy 
Combination chemotherapy of PZQ and oxamniquine has been investigated but the findings 
have not shown convincing evidence of superior benefit to PZQ alone [90, 96]. Not only 
oxamniquine is ineffective against the immature stage of the parasite like PZQ but also it is 
only effective against Schistosoma mansoni [90]. Therefore, the combination of PZQ and 
oxamniquine was not recommended for use in the treatment and control of schistosomiasis 
worldwide due to limited broad antihelminthic activity against different parasite stages and 
species. 
1.8.3.2 Combination therapy of PZQ and artemisinin derivatives 
PZQ is not effective against immature or juvenile worms [46, 48]. Mass PZQ administration 
leaves behind the immature parasites, which after 4 to 6 weeks, they grow to the matured stage 
and start laying eggs [1]. Hence the prevalence and intensity of infection may go back to the 
pre-treatment levels. As indicated earlier, this shortcoming of PZQ has partly contributed to 
the failure to control and eliminate schistosomiasis in endemic countries.  A broader 
antihelminthic approach supplementing PZQ with a new antischistosomal drug targeting 
different parasite development stages and/or having a different mechanism of action would not 
only increase the efficacy but also reduce the risk for PZQ resistance [93].  
Artemisinin derivatives (e.g. Artemether, Artesunate, and Dihydroartemisinin) have been 
reported to have high efficacy against immature or juvenile worms apart from their antimalarial 
activity [48]. Artemisinin combined with PZQ has been tested to treat schistosomiasis and has 
shown success in improving the cure rates [97-99]. PZQ and artemether or artesunate 
combination have performed better in schistosomiasis treatment than PZQ alone, and the 
combination has been reported suitable for the treatment of patients with repeated exposure to 
infected water [98, 99]. Dihydroartemisinin, a derivative of artemisinin has shown high activity 
against juvenile worms (schistosomula) of Schistosoma mansoni [100]. However, a concern is 
raised on artemisinin use as monotherapy combined with PZQ in settings where malaria is also 
endemic, like SSA, due to the risk of developing artemisinin resistance in malaria parasites 
[101]. Artemisinin derivatives remain key drugs for the treatment of malaria worldwide [102].  
Therefore, in malaria-endemic areas, the use of artemisinin-based combination therapy (ACTs) 
combined with PZQ is a better option as the risk of artemisinin resistance is greatly reduced 
[72]. In such combination, artemisinin is protected by a long-acting partner drug, e.g., 
piperaquine or Lumefantrine. In fact, ACTs alone have shown high efficacy (100% cure rate) 
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against schistosomiasis when given to treat malaria in patients co-infected with 
schistosomiasis, with a small sample size being the limitation in those studies [103-105]. 
Currently, there is no data on the treatment efficacy and safety of the combination of PZQ and 
ACTs, such as DHP for the treatment and control of schistosomiasis. In this PhD thesis, the 
efficacy and safety of PZQ and DHP combination therapy versus PZQ alone has been 
investigated for the treatment and control of intestinal schistosomiasis. DHP is a first-line 
antimalarial drug used for the treatment of uncomplicated malaria [102]. DHP was chosen over 
other ACTs (e.g. Artemether Lumefantrine) because of its easy schedule of administration 
(once per day for three days) [102] and has not extensively used for malaria treatment in most 
parts of SSA, including Tanzania [106] hence less drug pressure. DHP also has long post-
prophylaxis protection against malaria, which will offer protection to children who remain to 
be a vulnerable population against malaria in SSA [107].  
1.9 DRUG-DRUG INTERACTION BETWEEN PRAZIQUANTEL AND 
DIHYDROARTEMISININ-PIPERAQUINE  
In general, many factors may influence treatment outcomes, including the drug's inability to 
eliminate a parasite in one of its developmental stages of the life cycle, sub-optimal drug 
concentrations, use of sub-standard drugs, drug-drug interaction, individual genetics, and drug 
resistance [46, 93]. PZQ is sourced from the WHO pre-qualified drug companies; therefore, it 
is unlikely that the available PZQ in the market is sub-standard, although this cannot be 
guaranteed by 100%. On the other hand, much is still unknown about the pharmacokinetic of 
PZQ (i.e., plasma drug levels) in schistosomiasis infected children when used as a single dose 
[108]. With the introduction of combination therapy for schistosomiasis treatment, like in any 
drug combination therapy, there is a risk of drug-drug interactions if the combined drugs share 
the same metabolic pathway [109]. Drug-drug interactions may increase or decrease PZQ 
plasma concentration and further compromise schistosomiasis cure rates and adverse events 
profile [78].  
Dihydroartemisinin (DHA), an artemisinin derivative, is mainly metabolized via 
glucuronidation catalyzed by UDP-glucuronosyltransferases (UGTs), in particular UGT1A9 
and UGT2B7 [110]. While both PZQ and piperaquine (PPQ) (aminoquinoline derivative) are 
metabolized by cytochrome P450 enzymes (CYP450), e.g. CYP3A4/5, and this poses a risk 
for drug-drug interactions [111, 112]. Chloroquine, which is also an aminoquinoline derivative 
similar to PPQ [113], has been found to reduce the bioavailability and maximum concentration 
(Cmax) of PZQ in humans [114].   
Therefore, it is important to assess pharmacokinetic interactions of clinical significance when 
PZQ and DHP are used in combination chemotherapy. To the best of our knowledge, no study 
has assessed drug-drug interaction between PZQ and DHP. A review done by Utzinger J et al 
to assess combination chemotherapy of schistosomiasis recommended measurement of drug 
levels of the drugs used in combination therapy to treat schistosomiasis so that a link can be 
made with treatment outcomes both therapeutic efficacy and safety [90]. This PhD thesis 
investigated the effect of DHP on the pharmacokinetics of PZQ among infected school children 
to cover the existing gap. 
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1.10 EFFECT OF PHARMACOGENETICS VARIATIONS ON PRAZIQUANTEL 
PLASMA CONCENTRATION AND SCHISTOSOMIASIS TREATMENT 
OUTCOMES 
PZQ is primarily metabolized by CYP450 enzymes, including CYP3A4, CY3A5, CY2C19 
and CYP2C9 [111]. Most of these metabolizing enzymes are polymorphic, displaying inter-
individual variability in enzyme optimal function [115]. The change in enzyme activity due to 
genetic polymorphism in some individuals may affect plasma drug concentration, treatment 
efficacy and the incidence of treatment-associated adverse events [115]. CY3A4 has been 
described as a major metabolizing enzyme for most drugs used to treat tropical infections [115]. 
In malaria treatment, the CYP3A4 genotype was associated with treatment outcomes among 
the Tanzanian population treated with Artemether Lumefantrine [116]. On the other hand, 
CYP3A5 has been reported to be expressed mostly in the black population and is considered 
the most pharmacologically active CYP450 in the African population [117]. Studies have 
reported that most inter-population differences in CYP3A5 genotype are due to CYP3A5*3 
[115]. The lowest frequency of mutation in CYP3A5*3 has been reported in the Sub-Saharan 
population [115]. 
The sub-family CYP2C has been reported to metabolize about 20% of all CYP450 substrates. 
CYP2C9 and CYP2C19 are among the pharmacologically active CYP enzymes in the CYP2C 
sub-family and are also polymorphic. For example, for CYP2C19, about 3.6% of the Tanzanian 
population have been phenotyped as poor metabolizers in previous studies [118]. 
Studies conducted in other infectious diseases such as HIV, Tuberculosis, and malaria have 
shown the influence of genetic variations on plasma drug concentrations and treatment 
outcomes, both efficacy and safety [116, 119-122]. However, data on the effect of 
pharmacogenetics variations on PZQ plasma concentration and schistosomiasis treatment 
outcomes are lacking [78, 123]. To the best of our knowledge, no pharmacogenetics study has 
been conducted to assess the relevance of pharmacogenetics variations on PZQ plasma 
concentration and schistosomiasis treatment outcomes despite the reported variability in 
plasma PZQ concentration, cure rates, and adverse events profile between populations in 
previously reported studies [80, 87].  
Although the current approach of schistosomiasis treatment and control using MDA is a 
challenge for the individualization of treatment (genotype-based), data on the effect of 
pharmacogenetics variations on PZQ plasma concentration and schistosomiasis treatment 
outcomes are necessary for immediate future use. Pharmacogenetics data utilization efforts 
have also been recently intensified in Africa [124].  This PhD thesis investigated the role of 
pharmacogenetics variations on PZQ plasma concentration and schistosomiasis treatment 
outcomes, both efficacy and safety to cover the existing gap.
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2 AIM OF THE RESEARCH  
The main aim of the PhD thesis was to optimize schistosomiasis treatment outcomes among 
infected school children. This was done through a randomized, open-label, non-inferiority 
clinical trial to assess the efficacy and safety of PZQ and DHP combination therapy against 
PZQ alone for treatment and control of intestinal schistosomiasis. 
2.1 SPECIFIC OBJECTIVES 
1. To investigate the prevalence of intestinal schistosomiasis and its association with 
malaria, anaemia and nutritional status among school children in North-western 
Tanzania (paper 1) 
 
2. To assess the efficacy and safety of single-dose PZQ for treatment of Schistosoma 
mansoni infection among school children in North-western Tanzania (paper 2) 
 
3. To assess the efficacy and safety of PZQ and DHP combination therapy versus PZQ 
alone for treatment of Schistosoma mansoni infection among school children 
(paper 3) 
 
4. To assess pharmacokinetic drug-drug interaction and its clinical relevance between 
PZQ and DHP following coadministration for treatment of intestinal 
schistosomiasis (paper 4)  
 
5. To investigate the effect of pharmacogenetics variations on PZQ plasma 






3 MATERIALS AND METHODS 
3.1 STUDY SETTING 
The field work for the PhD research project was conducted in Nyamikoma village, Busega 
district, Simiyu region in North-Western Tanzania in collaboration with the National Institute 
for Medical Research (NIMR) Mwanza research centre (Figure 4). The North-western region 
of Tanzania around the Lake Victoria basin is one of the highly affected areas in the country, 
particularly with Schistosoma mansoni infection (Figure 1) [35]. Nyamikoma village, a rural 
area, located at latitude 2° 19' 59" S and longitude 33° 40' 59" E along the shores of Lake 
Victoria, was purposely selected for this study due to high endemicity of intestinal 
schistosomiasis and accessibility to NIMR Mwanza research centre. The project involved 
collecting blood and plasma samples that needed to be stored at -80 ͦ C on daily basis and 
therefore, accessibility of the study site was vital for the success of sample transportation and 
storage.  
According to the  Tanzania 2012 population and housing census, the Busega district had about 
203,597 people [125]. The district has two rainfall patterns, light rain from October to 
December and heavy rain from March to May of every year. The mean temperature is between 
18 ͦ C to 20 ͦ C during the rainy season and up to around 32 ͦ C in the dry season. The dominant 
tribe is Sukuma though other tribes such as Kurya and Jita are found. Fishing and farming of 
both crops and animals are the main economic activities around the district. Lake Victoria is 
the main source of water for all human needs in the study area. 
The laboratory work (pharmacokinetics and pharmacogenetics analysis) was done at the 





Figure 4: Map of Tanzania showing Simiyu Region and the study site (Nyamikoma village) 
located along the shores of Lake Victoria in Busega district 
3.2 STUDY DESIGN AND POPULATION 
To achieve the overall goal of the PhD project, different study designs and populations were 
used in the sub-studies, as presented in Figure 5. In sub-study 1, a cross-sectional study was 
conducted among 830 eligible school-aged children to assess the prevalence and correlates of 
intestinal schistosomiasis (paper I).  In sub-study 2, an efficacy and safety surveillance study 
was conducted among children who tested positive for Schistosoma mansoni infection and 
were treated with single-dose PZQ (n = 341) (paper II). Sub-study 3 was a randomized, open-
label, non-inferiority clinical trial among infected children who were treated with either PZQ 
alone (n = 341) or PZQ plus DHP combination therapy (n = 298) (paper III). In sub-study 4, a 
two-arm pharmacokinetic study was conducted on a randomly selected sample of 64 children 
treated with PZQ + DHP combination (n = 32) and PZQ alone (n = 32) to assess drug-drug 
interaction between PZQ and DHP and its clinical significance (paper IV). Sub-study 5 was a 
pharmacogenetics-pharmacokinetics-pharmacodynamics study conducted among children 
involved in sub-study 2 (paper II) to assess the impact of pharmacogenetics variations on PZQ 











3.3 DATA COLLECTION METHODS 
3.3.1 Collection of stool samples, processing and examination of 
Schistosoma mansoni infection 
Two fresh stool samples were collected on consecutive days from each enrolled participant, 
both before treatment (paper I) and after treatment (paper II, III and V). Following treatment, 
stool samples were collected at three weeks (paper II & V) and eight weeks (paper III) after 
treatment to assess drug efficacy [46, 90]. Two duplicate thick slides were prepared from each 
stool sample using the Kato Katz method [126]. Microscopic examination of the prepared 
slides was done 24 hours after preparation to allow adequate staining of the schistosome’ eggs 
(with methylene blue) [127]. The intensity of infection or egg per gram of stool (epg) for each 
study participant was calculated by multiplying the average eggs count from all four slides with 
a constant factor of 24. Baseline infection intensity was classified according to the WHO 
guidelines [12] as presented in Table 3. Ten percent of the slides, both positive and negative 
for Schistosoma mansoni infection were re-examined by an external technician for quality 
assurance [128, 129].  







Schistosoma mansoni 1 – 99 epg 100 – 399 epg ≥ 400 epg 
Schistosoma 
haematobium 
< 50 eggs/10 ml  ≥50 eggs/10 ml 
Source: Schistosomiasis: progress report 2001 - 2011, strategic plan 2012 – 2020 [12]. 
3.3.1.1 Assessment of drug(s) efficacy following PZQ treatment 
In paper II, assessment of drug efficacy was done by cure and egg reduction rates at three 
weeks post-treatment according to the WHO guidelines [46]. In paper V, assessment of PZQ 
efficacy was done by cure rate. The WHO guideline recommends assessing drug efficacy 
between 14 and 21 days after treatment to avoid parasite-related confounding factors. The 
chosen follow-up period allows adequate time to release schistosome’ eggs following treatment 
and avoids the effect of immature parasites, which are less sensitive to PZQ [46]. In paper III, 
the assessment of efficacy was done by cure and egg reduction rates at both three weeks and 
eight weeks post-treatment due to the biology of the parasite development from immature to 
mature parasite, a process taking 4 to 6 weeks [1, 130]. The eight-week follow-up visit was the 
main focus of this study and has also been recommended previously [90]. 
3.3.2 Diagnosis of malaria 
 A finger prick blood 100 µL was collected and used to detect malaria parasites using SD 
Bioline malaria Ag P.f/Pan Malaria Rapid Diagnostic Test (MRDT) (SD Standard Diagnostics, 
Inc, Korea). The results for malaria test were recorded as positive or negative. Studies have 
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indicated high sensitivity and specificity of the rapid diagnostic test compared to traditional 
microscopy in diagnosing malaria [131, 132]. Patients who were malaria positive were 
excluded from the study and treated according to the malaria treatment guidelines [102]. Only 
those who were malaria negative and intestinal schistosomiasis positive were enrolled in the 
study. Malaria was also assessed as a predictor of intestinal schistosomiasis infection (paper 
I).  
3.3.3 Estimation of haemoglobin concentration 
Haemoglobin concentration was determined using the HemoCue Hb 201+ method in g/dL 
(HemoCue AB Angelholm, Sweden). The method is effective and suitable in resource-limited 
settings [133]. Haemoglobin concentrations were then classified as mild (11.0 – 11.4 g/dL), 
moderate (8.0 – 10.9 g/dL) and severe anaemia (< 8 g/dL) based on the WHO guideline [134]. 
The presence of anaemia was assessed as a predictor of intestinal schistosomiasis infection 
(paper I), cure rate and treatment-associated adverse events (paper II, III and V). 
3.3.4 Assessment of nutritional status 
At the baseline survey, anthropometric measurements such as body weight (kg) and height 
(cm) were measured from each participant to assess nutritional status (paper I). Body Mass 
Index (BMI) for age Z score (BAZ) and height for age Z score (HAZ) for each participant were 
then calculated using the WHO Anthro Plus software version 1.0.4 [135]. Children with HAZ 
and BAZ scores less than two standard deviations were considered stunted and wasted. 
Stunting and wasting were also assessed as predictors of intestinal schistosomiasis infection 
and intensity (paper I), cure rate and adverse events following treatment (paper II, III and V).  
3.3.5 Monitoring of adverse events  
CRFs were used to collect information regarding adverse events, including their presence and 
severity. Treatment-associated adverse events were assessed within four hours after drug intake 
(paper II and III). It has been reported previously that most PZQ-related adverse events occur 
within this time following its intake [136, 137].  Therefore, monitoring of adverse events during 
this crucial time after the addition of DHP was important. Future studies should consider the 
assessment of safety for a much longer follow-up time. The treatment-associated adverse 
events were also linked to pharmacogenetics of PZQ in paper V. 
3.3.6 Laboratory analyses of whole blood and plasma samples  
3.3.6.1 Quantification of PZQ, enantiomers and trans-4-OH-PZQ concentrations in 
plasma samples 
In paper IV, blood samples (2 mL) were collected at 0, 1, 2, 4, 6 and 8 h post-dose from 64 
study participants who received either PZQ and DHP combination (n = 32) or PZQ alone (n = 
32). The blood samples were collected into heparinized vacutainer tubes using an indwelling 
intravenous catheter maintained in the antecubital arm vein and immediately centrifuged at 
1,000 rpm for 10 minutes to obtain plasma, which were kept at -80 °C freezer until analyzed. 
LC-MS/MS equipment (Thermo Scientific) using an enantioselective method was developed 
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to quantify R-PZQ and S-PZQ concentrations based on a recent validated method described by 
Kovac et al., [138]. Total PZQ concentration was obtained by summing R-PZQ and S-PZQ 
concentrations. In brief, plasma calibration samples were freshly prepared by spiking blank 
plasma samples with rac-PZQ and were included in each analytical run. Quality control 
samples were also prepared by spiking plasma blanks to obtain low, medium, and high 
concentrations for both R-PZQ and S-PZQ. The quantification range of the method was 1 to 
1500 ng/mL for both R-PZQ and S-PZQ. 
For extraction of analytes of interest, 100 µL of plasma samples went through protein 
precipitation with 200µL of internal standard solution (50 ng/mL of rac-PZQ-d11 in methanol) 
and then vortexed for 10 seconds followed by centrifugation for 5 min at 2100×g. 150 µl of the 
supernatant was diluted with 75 µL MilliQ water and 5 µL was injected onto the LC-MS/MS 
system. The chromatographic system was using a Chiralpak AGP 2.0 × 100 mm, 5 µm column 
(Chiral Technologies Europe, Illkirch, France) with 10 mM ammonium acetate: isopropanol 
98:2 (v/v) pH 8 as mobile phase with a flow rate of 0.3 mL/min. The chromatographic run was 
22 min, and with the use of the parallel two-channel capacity, injection to injection time was 
11 min. R-PZQ eluted first, followed by S-PZQ with a difference of 1.9 min. PZQ was 
monitored by the transition m/z 313.2>202.9 and the IS rac-PZQ-d11by 324.2>204.1. The 
calibration curve was constructed by linear regression of the analyte/internal standard area 
ratios with an applied weighing of 1/x2. Accuracy was within ±5% except for LLOQ levels, 
where it was within ±12%. Precision was below 5 CV% except for LLOQ (below 13 CV %). 
The final concentrations for R-PZQ, S-PZQ and total PZQ were analyzed by non-
compartmental method to obtain the AUCs, Cmax, half-life (t1/2) and Tmax. The pharmacokinetic 
parameters were compared between treatment groups to assess bioequivalence (paper IV).  
Due to the long retention time for each sample in the enantioselective method, we also 
investigated which single sampling time-point better correlate with AUC0-8h among those 
treated with PZQ alone for quantification of total PZQ and metabolite trans-4-OH-PZQ. We 
found that plasma samples collected at four hours post-PZQ administration for total PZQ better 
correlate with AUC0-8h  (Unpublished data).  
Therefore, in paper V, plasma samples collected at four hours post-PZQ were analyzed. Only 
study participants treated with PZQ alone were included in this study (paper II). The UPLC-
MS/MS method for quantification of PZQ and trans-4-OH-PZQ was adapted from Astra 
Zeneca laboratories (Sweden) and was recently used by Nleya et al., 2019 [139] with minor 
modifications. In brief, plasma calibration samples were freshly prepared by spiking blank 
plasma samples with rac- PZQ and trans-4-OH-PZQ and were included in each analytical run. 
Quality control samples were also prepared by spiking plasma blanks to obtain low, medium, 
and high concentrations for both PZQ and trans-4-OH-PZQ. The quantification range of the 
method was 3.9 to 2500 ng/mL for PZQ and 31.2 to 50000 ng/mL for trans-4-OH-PZQ.  
For extraction of analytes of interest, 50 µL of plasma samples went through protein 
precipitation with 150 µL of internal standards solution (25 nM of rac- PZQ -d11 and 25 nM 
of trans-4-OH-PZQ -d5 in 50:50 mixture of acetonitrile: methanol) and the mixture was 
vortexed for 3 minutes followed by centrifugation for 20 minutes at 3220 g at 4 ͦ C. Then, 75 
µl of the supernatant was diluted with 75 µL MilliQ water and 5 µL was injected onto the 
UPLC-MS/MS system for analysis. The chromatographic system was using an Aqcuity 
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UPLC®HISS T3 column (2.1 × 50 mm, 1.8 µm (Waters, Ireland). The mobile phase consisted 
of solvent A (0.1% formic acid and 2% acetonitrile in water) and solvent B (0.1% formic acid 
in acetonitrile) with a flow rate of 0.8 mL/min. The column temperature was maintained at 60 ͦ 
C.  
The chromatographic run was 4.7 minutes, starting at 4% of solvent B with an increase to 70% 
of solvent B at 2.6minutes. From 3.1 minutes the column was washed with 96% of solvent B 
until 4.1 minutes, with two dips to 4% of solvent B in the middle to ensure efficient washing. 
Column re-equilibration was done from 4.2 to 4.7minutes, but was in effect longer when 
including the injection time.Trans-4-OH-PZQ eluted first at a retention time of 1.15 minutes 
followed by PZQ at 1.89 minutes (Figure 6). PZQ was monitored by the transition m/z 
313.2>203.1 and the IS rac- PZQ -d11by 324.2>204.1 and for trans-4-OH-PZQ by the 
transition m/z 313.2>203.1 and the IS trans-4-OH-PZQ -d5 by 324.2>204.1. Because of the 
very high concentrations of trans-4-OH-PZQ in the samples, a detuned (sub-optimized) MS 
method was used by decreasing the collision energy setting for that transition.  
 
Figure 6. Chromatography showing retention times and peak shape for PZQ and trans-4-OH-
PZQ with internal standards. 
Quantification of PZQ and trans-4-OH-PZQ was done using Target Lynx software (Waters). 
The calibration curves were constructed by linear regression of the analyte/internal standard 
area ratios, with a quadratic curve fit and an applied weighing of 1/x. A minimum of 12 
calibration points were used, and calibrators were injected at start and end of each analysis. 
Three quality control samples were injected at regular intervals throughout the analyses. The 
PZQ and trans-4-OH-PZQ concentrations were estimated based on the ratio of the analyte peak 
area to the internal standard area.  
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Accuracy and recovery of the method was measured from 3 quality control samples each, at 
low (QCL), mid (QCM), and high (QCH) levels. For PZQ, recovery was 105% for QCL, 87% 
for QCM, and 100% for QCH at 5, 8.7, and 1 % relative standard deviation (RSD), respectively. 
For trans-4-OH-PZQ the recovery was 104, 109, and 97.11 for the three QC levels, and 
accuracy was 2.6, 2.7, and 1.9 % RSD. The precision for PZQ was measured by injection of 6 
replicates and was 6.7 % RSD at LLOQ, and 4.1 % RSD at QCH. For trans-4-OH-PZQ, the 
area precision was 6.4 % RSD at LLOQ and 5.3 at QCH. The calibration curves for both PZQ 
and trans-4-OH-PZQ had a coefficient of determination (r2) of >0.98. No carry-over was 
detected for the compounds analyzed.  
Both analytical methods (paper IV and V) were partially validated according to the European 
Medicines Agency Guideline on bioanalytical method validation [140]. 
3.3.6.2 Collection of the whole blood sample, Genomic DNA isolation and Genotyping 
Before drug administration, 2 mL of whole blood samples were collected in an EDTA 
vacutainer tube from each participant.  The blood samples were temporarily stored -80 ͦ C at 
NIMR Mwanza research centre laboratory before being shipped to the Department of 
Laboratory medicine, Karolinska University Hospital Huddinge (Stockholm) for analysis.  
According to the manufacturer’s instructions, genomic DNA was isolated from peripheral 
leucocytes using Qiagen QIAamp DNA Midi Kit (Qiagen GmbH, Germany). The isolated 
genomic DNA were then temporarily stored at -20 ͦ C until time for genotyping. 
Genotyping for common variant alleles CYP3A4 (*1B), CYP3A5 (*3,*6,*7), CYP2C19 
(*2,*3,*17) and CYP2C9 (*2,*3) relevant for PZQ metabolism were done [111]. Genotyping 
was performed using TaqMan® drug metabolism genotyping assay reagents for allelic 
discrimination (Applied Biosystems Genotyping Assays) with the following ID numbers for 
each SNP: C__11711730_20 for CYP3A4*1B (−392A>G, rs2740574), C__26201809_30 for 
CYP3A5*3 (c.6986A4G, rs776746), C__30203950_10 for CYP3A5*6 
(g.14690G4A,rs10264272), C__32287188_10 for CYP3A5*7 (g.27131_27132insT 
rs41303343), C__25986767_70 for CYP2C19*2 (rs4244285), C__27861809_10 for 
CYP2C19*3 (rs4986893), C__469857_10 for CYP2C19*17 (rs12248560), C__25625805_10 
for CYP2C9*2 (rs1799853), and C__27104892_10 for CYP2C9*3 (rs1057910). Genotyping 
was done using 7500 Fast Real-Time PCR (Applied Biosystems, USA).  
The pharmacogenetics data were analyzed to obtain the genotype and allele frequencies.  The 
CYP3A4, CYP3A5, CYP2C19 and CYP2C9 genotypes were then linked to plasma 
concentrations (PZQ, trans-4-OH-PZQ and metabolic ratio (trans-4-OH-PZQ/PZQ)) and 
schistosomiasis treatment outcomes both efficacy and safety (paper V). 
3.4 DATA MANAGEMENT AND STATISTICAL ANALYSIS 
Data were collected in paper work and then transferred into a database. The database was 
created by the Data Management Unit (DMU) of the National Institute for Medical Research, 
Mwanza Research Centre, using Census and Survey Processing system (CSPro) software (U.S 
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Census Bureau, USA). Data collection was done by well-trained research assistants of NIMR 
Mwanza research centre under supervision and guidance of PhD student. The research team 
was trained on Standard Operating Procedures (SOPs) and Good Clinical and Laboratory 
Practices (GCLP). The collected data was cleaned and data analysis was done using Statistical 
Package for Social Sciences (SPSS) Windows version 20 (SPSS, IBM Corp, Armonk, NY, 
USA) for paper I, II, III and V and R statistical software (version 4.0.2 and PKNCA package 
version 0.9.4) for paper IV.   
Descriptive statistics was used to analyze socio-demographic and baseline characteristics of 
the study participants (paper I, II, III, IV and V). Categorical variables were presented as 
proportions, while continuous data were summarized as mean ± standard deviation (SD) or 
median (Interquartile range – IQR) depending on the normality distribution of data. Chi-square 
or Fishers exact test was used to assess association between categorical variables (paper I, II, 
III, IV and V). Independent sample t-test was used to compare the means of normally 
distributed data, while Wilcoxon Mann, Whitney U test was used to compare continuous data 
that were not normally distributed (paper I, II, III and IV).  
In addition to the above analysis, in paper I, a negative binomial regression model was used to 
assessing for the predictors of baseline infection intensity (epg) (count outcome variable). This 
test was chosen over Poisson regression model because there was over dispersion of the epg 
data (variance > mean). To apply the Poisson regression model, the mean should be equal to 
the variance. Spearman correlation test was used to assess the relationship between two 
continuous data i.e. infection intensity (epg) vs haemoglobin concentration. Univariate and 
multivariate regression analysis was used to assess for the predictors of intestinal 
schistosomiasis infection (binary outcome variable). All variables with p < 0.2 from the 
univariate analysis were included in the multivariate regression model. 
In paper II, univariate and multivariate regression analysis was used to assess for the predictors 
of cure at three weeks post-treatment. All variables with p < 0.3 from the univariate analysis 
were included in the multivariate regression model. 
In paper III, two-way ANOVA was used to compare the baseline infection intensity (epg) 
between infection intensities (light to heavy infections) and treatment groups. This statistical 
test is suitable when comparing count variable between two categorical variables. Univariate 
and multivariate regression analysis was also used to assess for the predictors of cure at eight 
weeks post-treatment, which was the main focus of this study. Predictor variables with p < 0.2 
from the univariate analysis were included in the multivariate regression model. 
In paper IV, the pharmacokinetics parameter values were log-transformed and then anti-logged 
to obtain geometric means. The concentrations, Cmax and AUCs values were dose-normalized 
by dividing their values by received dose. An independent sample t-test was used to compare 
the means of log-transformed AUC0-8h. A linear mixed-effect model (stepwise manner) was 
used to determine subject characteristics influencing Noncompartmental pharmacokinetics 
parameters values (Cmax AUCs and half-life). The Geometric mean ratio (GMR) of a 
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pharmacokinetic parameter was calculated as a ratio of PZQ+DHP (test) to PZQ (control). The 
90% CI of the GMR of a pharmacokinetic parameter was used to assess for bioequivalence 
between treatment arms, where any interval outside 80, 125% was considered not 
bioequivalent. 
In paper V, Pearson’s chi-square was used to compare the observed and expected genotypes 
frequencies according to the Hardy-Weinberg equilibrium. One-way ANOVA was used to 
compare log-transformed PZQ, trans-4-OH-PZQ concentrations and the metabolic ratio 
between different CYP450 genotypes. Pearson’s chi-square or Fisher's exact test depending on 
test appropriateness was used to assess the association between cure rates and adverse events 
and CYP450 genotypes. Univariate and multivariate regression analysis was used to assess for 
the predictors of cure at three weeks and adverse events within four hours post-dose. All 
variables with p < 0.2 from the univariate analysis were included in the multivariate regression 
model. 
In all multivariate regression analyses done in this thesis, a variable with a p < 0.05 was 
considered as a significant predictor. The Hosmer and Lemeshow test was used to assess the 
goodness of fit of the multivariate models.  
3.5 ETHICAL CONSIDERATIONS 
Ethical and scientific approval to conduct this study was granted by the Medical Research 
Coordination Committee (MRCC) of the National Institute for Medical Research, Dar es 
Salaam Tanzania (Ref. No. NIMR/HQ/R.8a/Vol.IX/2343 and renewals 
(NIMR/HQ/R.8c/Vol.II/953 & NIMR/HQ/R.8c/Vol.I/1212) and the Muhimbili University of 
Health and Allied Sciences Institutional Review Board (Ref. No.2016-5-25/AEC/Vol.X/03). 
The clinical trial was then registered with the Pan African Clinical Trial Registry (PACTR), 
registration number PACTR201612001914353. We also applied for an ethical permit from the 
Stockholm Ethics Committee for the work conducted in Sweden (pharmacokinetics and 
pharmacogenetics studies) (Ref.No.2020-00845).  
Before enrolment, comprehensive information about the study was given to all 
parents/guardians and participating children in the national language (Swahili) and local 
language (Sukuma). Thereafter, written informed consent from parents/guardians and assent 
from participating school children were obtained. Participation in the study was purely 
voluntary, and participants were free to withdraw from the study at any time without any 






4 RESULTS AND DISCUSSION 
Overall, a total of 830 school-aged children were enrolled in this PhD project.   Out of 830 
children, 752 (90.6%) tested positive for intestinal schistosomiasis (paper I). Of those who 
tested positive for intestinal schistosomiasis, 84.9% (639/752) were eligible and consented to 
participate in the clinical trial and followed up to 8 weeks post-treatment, 341 received PZQ 
alone, and 298 received PZQ and DHP combination therapy (paper III). Children who received 
PZQ alone were also followed at three weeks post-treatment to assess the efficacy and safety 
of PZQ as per the WHO guideline as presented in Figure 5.  
A total of 100 children out of 752 (13.3%) who tested positive for intestinal schistosomiasis 
declined treatment during the study period, where 57 children declined before and 43 children 
after random allocation in the test group (Figure 5). The decline rate to treatment of13.3% 
among those who tested positive for intestinal schistosomiasis in this study may highlight one 
of the challenges (i.e. low treatment coverage) in the efforts to control and eliminate 
schistosomiasis in endemic countries [56]. The untreated children will serve as a reservoir of 
infection and continue transmitting the disease in the community [6]. Unfortunately, this study 
did not investigate the reasons for the decline of treatment. However, other studies in Africa 
reported participation in daily economic activities, bitter taste of the drug, school enrollment, 
and settlement in a village, and previous exposure to drug-related adverse events as significant 
contributing factors [141, 142]. Therefore, the national NTDs control and elimination programs 
should not only focus on drug availability and distribution in the at-risk populations but also 
address the factors contributing to the low treatment coverage. 
4.1 Prevalence and correlates of intestinal schistosomiasis infection   among 
school children (paper I) 
 A total of 830 school-aged children aged 7 – 19 years old were eligible and recruited in the 
baseline survey. The mean age (±SD) was 11.7 ± 1.9 years.  At recruitment, 155 children out 
of 830 (18.7%) reported pre-treatment abdominal pain. Out of 830 recruited children, 459 
(55.3%) had a normally formed stool, while 266 (32%) and 105 (12.7%) had soft and loose 
stool, respectively. 
Prevalence and intensity of intestinal schistosomiasis 
Out of the 830 children examined, 752 (90.6%) were infected with intestinal schistosomiasis. 
Children below the age of 12 years were more infected (64.6%, 536/830) than those above 12 
years (26.0%, 216/830) (p < 0.001). There was no significant difference in the prevalence of 
infections between males and females.  All children who had either soft (n=266) or loose stool 
(n=105) at enrolment were found to be infected with intestinal schistosomiasis (Table 1&2 – 
paper I) (p = < 0.001). Out of the 155 who had abdominal pain during enrolment, 140 children 
(16.9%, 140/830) were infected with intestinal schistosomiasis. However, there was no 
association between pre-treatment abdominal pain and intestinal schistosomiasis infection 
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(p=0.89). On both univariate and multivariate logistic regression analysis, lower age was the 
only significant predictor of intestinal schistosomiasis infection (Table 4 – paper 1). 
Overall, the study population was moderately infected with intestinal schistosomiasis, with the 
median infection intensity of 204 eggs per gram (epg) (IQR 54 – 457) as per the WHO guideline 
[12]. The majority of the participants had moderate (38.4%) to heavy infections (28.1%), while 
the light infection was 24.1%. Participants with loose and soft stools were had significantly 
higher mean epg of stool than those with formed stool (p < 0.001) (Figure 1 – paper 1). Based 
on the negative binomial regression model, being male, having loose stool, and stunting were 
found as significant predictors of high eggs counts (Table 3 – paper 1). 
Prevalence of malaria and association with intestinal schistosomiasis 
Out of 830 participants, 824 (99.3%) were available and provided blood samples for malaria 
testing, where 14 out of 824 (1.7%) were found to be malaria positive. There was no significant 
difference in malaria prevalence between age groups and sex (p > 0.05). A total of 13 out of 14 
who tested malaria positive were found to have malaria – intestinal schistosomiasis co-
infection, making a co-infection of 1.6% (13/824) in the study population and 92.8% (13/14) 
among those who were malaria positive. There was no significant association between malaria 
and intestinal schistosomiasis infections (p = 0.13) (Table 2 – paper 1). 
Prevalence of anaemia and association with intestinal schistosomiasis 
Like in malaria, 824 out of 830 (99.3%) of the children were available and provided blood 
samples to estimate haemoglobin concentration in g/dL. Out of 824, 203 (24.6%) of the 
children were found to be anaemic (haemoglobin concentration < 11.5 g/dL). Severe anaemia 
was observed in 2.3% of the children (19/824).  The median haemoglobin concentration of the 
study population was 12.6 g/dL (IQR 11.5 – 13.5). Children not infected with intestinal 
schistosomiasis had slightly higher haemoglobin concentration (12.8 g/dL) than infected ones 
(12.5 g/dL) (p = 0.93) (Figure 2 – paper 1). There was no association between anaemia and 
intestinal schistosomiasis infection (p = 0.36). 
Prevalence of undernutrition and association with intestinal schistosomiasis 
Prevalence of stunting and wasting were assessed in this study. A total of 241 out of 830 
(29.0%) and 94 out of 830 (11.3%) were found to be stunted and wasted, respectively. There 
was no significant association between intestinal schistosomiasis infection and neither stunting 
(p = 0.53) nor wasting (0.41). However, stunting was found to be a significant predictor of high 
egg counts among those infected (Table 3 – paper 1).  
The high prevalence and intensity of intestinal schistosomiasis observed in the study area 
despite five MDA rounds were similar to previous studies conducted around the Lake Victoria 
basin [27, 28]. Similar results were reported from other endemic areas in Sub-Saharan Africa 
[143]. These findings indicate that there are either hotspots or continuous transmission of the 
disease in the communities despite ongoing interventions. Lack of vaccine to complement 
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preventive chemotherapy has been sought as one of the major factors for the continued disease 
transmission in endemic countries [144]. Other factors include poor sustainability of MDA and 
vector control programs, especially in an area with high transmission and fragmented treatment 
coverage [56]. E.g. preschool children are excluded from the MDA campaign can serve as a 
reservoir of infection [145], low knowledge on disease transmission and prevention, poor 
sanitation and hygiene and lack of safe and clean water [146] as the communities rely on Lake’s 
water for all human needs. There was no MDA in 2016, a year before this study has commenced 
in the study area. The interruption of MDA (single-dose PZQ), which in itself seems not 
sufficient enough to control the disease in such settings with high transmission, may have 
contributed to the observed high prevalence of the disease.  
Pre-adolescents (≤ 12 years) were also found to be more infected than adolescents (> 12 years), 
which might indicate a carry-over of infection as preschool children are not involved in MDA. 
Even if a child is infected at three years old has to wait for at least 3 to 4 years to start primary 
education and get treatment [145]. Recent studies have shown a correlation between 
schistosomiasis infection prevalence between school-aged children and pre-school children 
[147]. Therefore, when the prevalence of infection is high in school children, it is equally the 
same in pre-school children. Early integration of pre-school children in mass drug 
administration presents a key step towards disease control and elimination efforts [148, 149].  
 Apart from preventive chemotherapy, previous studies have also indicated that control and 
elimination of schistosomiasis in endemic countries can be achieved by improving sanitation 
and hygiene and access to clean and safe water [150-152]. These factors are far behind in Sub-
Saharan Africa; therefore, eliminating schistosomiasis as a public health problem by 2030 may 
be a premature target in the region.  
The inability of PZQ to act against immature worms may be another major factor for the 
continued transmission of the disease in endemic countries [48, 72, 153], where the individuals 
are constantly infected and harbour more immature parasites. These juvenile parasites are left 
behind during PZQ MDA, and after 4 – 6 weeks, they attain their reproductive maturity and 
start laying eggs [1]. Therefore, there is a pressing need for an alternative treatment strategy 
that can either act on juvenile parasites or have a different mechanism of action to complement 
PZQ. So far, no documented report of PZQ resistance; however, an alarming threat of PZQ 
tolerance/resistance has been reported from field studies from SSA [70]. Hence the need to 
continuously assess disease prevalence and PZQ efficacy in the endemic setting as 
recommended by the WHO [46]. The WHO recommends assessing drug efficacy if the 
prevalence and intensity of infection are still high despite preventive chemotherapy [46]. 
Intestinal schistosomiasis infection was not significant associated with malaria, anaemia and 
undernutrition in the present study. Similar results have been reported previously [27, 28] 
except for anaemia which is associated with Schistosoma haematobium infection [26]. 
Nevertheless, the burden of anaemia and undernutrition continued to be high among school 
children, similar to what was reported in previous studies [27, 28]. These conditions may limit 
children from getting a better education.  
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4.2 Efficacy and safety of praziquantel for treatment of Schistosoma mansoni 
infection among school children (paper II) 
A total of 341 Schistosoma mansoni infected children (7-17 years) and treated with single-dose 
PZQ (40 mg/kg body weight) were enrolled in this study and followed for three weeks as per 
the WHO guidelines [46]. The mean age (±SD) of the population was 11.8 ± 1.7 years. About 
20.8% (71/341) of the participants had reported abdominal pain before treatment. The majority 
of the participants had moderate infection intensity (44.6%), as summarized in Table 1 of paper 
II. The median infection intensity of the study population was 222 epg (IQR 96 – 471).  
Efficacy of PZQ by cure and egg reduction rates 
The efficacy of PZQ was assessed based on cure rate and egg reduction rate (ERR) at three 
weeks post-treatment as per the WHO guidelines [46]. The cure rate was defined as the 
proportion of treated patients who were eggs positive at baseline and turned eggs negative at 
three weeks of the post-treatment follow-up visit. The cure rate was 81.2% (277/341) (95% CI 
76.8, 85.3%). There was no significant association between cure rate and age, sex, baseline 
infection intensity, stunting, wasting and anaemia (Table 2&4 – paper II). There was a 
significant drop in the level of infection intensity before and after treatment from light to heavy 
infection (Table 3 – paper II), e.g. heavy infection has dropped from 29.9% to 0.9% in the study 
population. The egg reduction rate was found to be 95% (95% CI 92.7 – 97.3%). There was no 
significant association between egg reduction rate and age (p = 0.12) and sex (p = 0.45). 
The observed cure and egg reduction rates in this study were within the acceptable range. Cure 
rate between 60% and 90% for Schistosoma mansoni [93] and an ERR of > 90% are considered 
satisfactory according to the WHO guideline [46].  Based on ERR, these results indicate that 
PZQ is still efficacious against Schistosoma mansoni. We have based on the ERR findings for 
evaluation of PZQ efficacy because the cure rate has been reported not to be a good indicator 
of PZQ efficacy, as detailed by Montresor A. et al. [154]. The use of ERR to assess PZQ 
efficacy has also been recommended by the WHO [46]. However, the lack of cure in 18.8% of 
the study participants points to the need for further research to optimize PZQ efficacy. Some 
studies have indicated that increased PZQ MDA rounds may be associated with low 
parasitological cure, especially with Schistosoma mansoni [91]; hence close monitoring of the 
drug efficacy is vital for early detection of reduced efficacy or drug resistance. This is especially 
important because, to date, there is no alternative drug to PZQ for treatment and control of 
schistosomiasis. 
PZQ treatment-associated adverse events (safety) 
Treatment-associated adverse events were assessed within four hours of PZQ administration, 
as reported previously in other studies [75, 137]. This is because, during this timeline, the 
majority of adverse events are observed following PZQ intake. Overall, a total of 28.7% 
(97/341) of the participants experienced adverse events. Post-treatment abdominal pain was 
experienced and reported by 26.7% (91/341) of the treated children, while 1.8% (6/341) 
reported vomiting. However, almost all adverse events were mild and transient. No serious 
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adverse was observed in this study, particularly neurological symptoms including dizziness, 
drowsiness or fainting. Post-treatment abdominal pain was significantly associated with 
baseline infection intensity, whereby children who had moderate (25.7%) to heavy infection 
(40.2%) experienced more adverse events compared to those with light infection (12.6%). 
Vomiting was significantly associated with anaemia, whereby anaemic children had more 
vomiting than non-anaemic children (Table 6 – paper II). 
PZQ has been associated with adverse events following intake. However, as observed in this 
study and reported in most previous studies [86, 155], most of PZQ associated adverse events 
were mild and resolve within four hours of drug administration. In this study, we have also 
observed a few adverse events. This might be due to the pre-treatment meal given to the 
children before drug administration as recommended by the WHO [46]. Therefore, based on 
the findings, PZQ is still safe and well-tolerable to the treated children. However, clinical 
examination may be considered before treatment to identify anaemic children who may need 
special monitoring following PZQ intake since vomiting was significantly associated with 
anaemia.  Unfortunately, the Lake Zone has been reported to have a high prevalence of 
schistosomiasis, and therefore, the need for PZQ MDA has been reported to have a high 
prevalence of anaemia as well [27, 28]. Similar to previous studies, post-treatment abdominal 
pain was associated with pre-treatment infection intensity [137]. Heavily infected children 
experience adverse events more than those with light to moderate infection.  
For that reason, assessment of adverse events during PZQ efficacy studies remains important 
since most studies estimated sample size based on the efficacy section, and it may be difficult 
to observe rare adverse events. There is a lack of studies based on active cohort event 
monitoring to assess the safety of medicines used to control and eliminate neglected tropical 
diseases in Sub-Saharan Africa, contrary to what is recommended by the WHO [82]. For 
example, recently, visual impairment was linked with PZQ MDA in the Eritrean population 
[156]. The WHO is making a close follow-up on the matter with proper methodology (i.e. 
active cohort monitoring) to establish a causal association [157]. Furthermore, studies to 
investigate the effect of pharmacogenetics variations on safety following PZQ are lacking 
despite the varying degree of reported adverse events between treated populations [85, 123]. In 
this thesis, this knowledge gap has been evaluated and is presented in paper V. 
4.3 Efficacy and safety of praziquantel and dihydroartemisinin-piperaquine 
combination versus praziquantel alone for treatment of intestinal 
schistosomiasis: non-inferiority trial (paper III) 
Out of 752 children who tested positive for intestinal schistosomiasis, 682 (90.7%) were 
eligible and consented to participate in the trial. These were randomized (1:1) based on 
infection intensity, where 341 were randomly allocated to receive PZQ alone, and 341 received 
PZQ and DHP combination. Since participation in the study was voluntary, and participants 
were free to withdraw from the study at any time, 43 children declined treatment from the PZQ 
and DHP combination arm after allocation (Figure 5). Therefore, 639 children were involved 
in the trial, of whom 341 children were treated with PZQ alone and 298 children with PZQ and 
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DHP combination. At enrollment, most participants had moderate infection intensity (43.8%) 
(Table 1 – paper III). After randomization, there was no significant difference between 
treatment groups (p > 0.05) except for stunting, where those on the PZQ arm were more stunted 
(34.3%) than PZQ and DHP arm (21.8%) (p < 0.001). However, there was no significant 
association between cure rates and stunting (p > 0.05).  
Cure and egg reduction rates between treatment groups 
At 3 weeks post-treatment, cure rates were 88.3% (95% CI 84.1- 91.4%) and 81.2% (95%CI 
76.7 – 85.0%) in the PZQ and DHP combination and PZQ, respectively (p = 0.01). The 
difference in cure rate between treatment groups was 7.1% (95%CI of the difference 1.48 – 
12.6%). At 8 weeks post-treatment, cure rates were 81.9% (95%CI 77.1 – 85.8%) and 63.9% 
(95CI 58.7 – 68.8%) in the PZQ and DHP combination and PZQ, respectively (p < 0.001). The 
difference in cure rate between treatment groups was 18% % (95%CI of the difference 11.2 – 
24.6%). Therefore, the overall cure rates at both follow-up visits were significantly higher in 
the PZQ and DHP combination than in the PZQ arm. At eight weeks post-treatment, cure rates 
were significantly higher in the PZQ and DHP combination than in PZQ across all levels of 
infection intensity (light to heavy infection) (p < 0.05). For instance, among those with heavy 
infections, at eight weeks post-treatment, cure rates were 75.9% in the PZQ and DHP 
combination versus 59.8% in the PZQ arm (p = 0.02) (Table 3 – paper 3). On both univariate 
and multivariate regression analysis to identify predictors of cure at eight weeks post-treatment, 
only type of treatment received was found to be a significant predictor (p < 0.001) (Table 4 – 
paper 3). At 8 weeks of post-treatment, ERR were also significantly higher in PZQ and DHP 
combination (93.6%, 95%CI 90.8 – 96.4%) than in PZQ arm (87.9%, 95%CI 84.4 – 91.4%) (p 
= 0.01). At three weeks of post-treatment, ERR were not significantly different between 
treatment groups (Table 5 – paper 3). 
These findings indicate that the combination of PZQ and DHP is more efficacious than PZQ 
alone to treat schistosomiasis. Similar results have been reported when PZQ and artemether or 
artesunate were co-administrated to treat schistosomiasis [97-99]. The combination therapy of 
PZQ and DHP can be considered for treatment and control of schistosomiasis, especially in the 
areas with high transmission of the disease and in malaria-endemic settings. As the risk of 
artemisinin resistance against malaria parasite is high with the use of artemisinin as 
monotherapy combined with PZQ [56], in settings where both schistosomiasis and malaria are 
endemic, the use of ACTs such as DHP in combination with PZQ may be a better option. The 
two diseases remain a major public health challenge, particularly in Sub-Saharan Africa [158]. 
Studies to investigate the usefulness of mass treatment of malaria in school children have been 
carried out in some Sub-Saharan countries. Intermittent preventive treatment (IPT) with mass 
administration of sulphadoxine-pyrimethamine plus piperaquine or amodiaquine in Congo 
[159], in Kenya [160], and Mali [161] and mass treatment using DHP in Uganda [162] in school 
children has shown promising results in terms of malaria prevention. The interventions also 
indirectly improved the burden of anaemia among school children.  
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The fact that the two diseases are overlapping in most countries in Sub-Saharan Africa, and 
children remain the most vulnerable population [163], studies have also been conducted to 
integrate mass treatment of malaria in existing NTDs control programs. A pilot study in Malawi 
has investigated the co-administration of PZQ and albendazole for NTDs and artemether 
Lumefantrine (ALU) for malaria and reported that the co-administration was well tolerated by 
the school children [164]. In Ghana, apart from reducing malaria prevalence and improving 
anaemia, the co-administration of malaria and helminths treatments was also associated with 
increased school participation and performance [165]. However, due to the complex 
administration schedule of ALU, DHP, which is once a day for three days, can be a good option 
in combination with PZQ for schistosomiasis and malaria control in school children [102]. 
DHP has a long half-life which offers much longer protection against malaria [107] and has 
not been extensively used for clinical management of malaria in Sub-Saharan Africa and hence 
less drug pressure [106]. Therefore, the national schistosomiasis and malaria control programs 
in Sub-Saharan Africa should consider working in collaboration and use PZQ and DHP 
combination to halt the burden of the two diseases, particularly in school children.  
On the other hand, repeated PZQ doses spaced 3-6 weeks apart have also been investigated for 
the treatment and control of schistosomiasis and shown better treatment outcomes by killing 
immature parasites left behind during the first dose of PZQ administration [71]. Although there 
is still ongoing debate regarding the usefulness of repeated PZQ doses versus cost and risk of 
accelerating PZQ resistance, its use in high transmission areas of the disease where a single 
annual PZQ dose is obviously not adequate cannot be underestimated. However, it is an 
obvious fact that repeated PZQ doses will be costly in endemic countries with limited resources 
where even annual single-dose PZQ administration is not sustainable. Furthermore, repeated 
doses will definitely increase PZQ use, and it has been reported that increased use of PZQ in 
MDA is associated with low cure rates and may accelerate the risk of parasites developing 
resistance against PZQ [91]. Indeed, PZQ resistance is a major concern among experts in the 
field since there is no alternative drug [92, 166]. Since the emergence of drug-resistant mutants 
is a direct result of selective pressure by repeated drug use, the chance of resistance to two 
drugs with a different mechanism of action is lower than single drug use, provided that 
resistance mechanisms are independent [94, 95].  
Accordingly, combination drug therapy is the current standard treatment strategy for infectious 
diseases such as tuberculosis, HIV and malaria, and it is a way to go for NTDs.  The risk of 
parasite resistance associated with repeated PZQ dose as a strategy can be overcomed with the 
proposed combination therapy of PZQ and ACTs such as DHP. PZQ is speculated to act mainly 
by disrupting the Ca2+ channels and finally the parasite’ outer tegument, while artemisinin 
works by inhibiting the schistosome-specific thioredoxin glutathione enzyme and/or reduction 
in schistosome glycogen and protein content [72, 167]. Thioredoxin glutathione enzyme has 
been reported to be a major potential target of drugs for NTDs [168]. However, despite better 
treatment outcomes shown by PZQ and DHP, further studies to investigate cost-effectiveness, 
feasibility in a wide community implementation and the usefulness of this combination therapy 
are important as DHP remains one of the key antimalarial drugs worldwide. 
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Treatment-associated adverse events  
Overall, 197 out of 639 treated children (30.8%, 95%CI 27.2 – 34.4%) experienced adverse 
events. Abdominal pain was observed in 27.1% (173/639) while vomiting in 3.4% (22/639) of 
the children. In the PZQ arm, a total of 97 out of 341 (28.4%, 95%CI 23.7 – 33.3%) of the 
children experienced adverse events. A slightly higher percent (33.6%, 95%CI 28.2 – 38.9%) 
(100/298) was observed in the PZQ and DHP arm. Without considering a kind of adverse event 
experienced by treated children, overall, there was no statistically significant difference in the 
incidence of adverse events between treatment groups (p = 0.16).  However, stratified by type 
of adverse events, vomiting was significantly higher among those treated with PZQ and DHP 
combination (5.4%) than PZQ alone (1.8%) (p = 0.01) (Table 6 – paper 3). Conversely, almost 
all adverse events observed were mild and transient, and no serious adverse event was 
experienced by treated children in both treatment groups.  
The findings suggest that the overall PZQ and DHP combination is equally safe to PZQ alone. 
Similar results were reported when PZQ was combined with artesunate as a monotherapy [97]. 
In this study, overall safety has been further maintained even with the addition of DHP. This 
finding is significant because both efficacy and safety need to be maintained. PZQ 
administration has been associated with adverse events, including vomiting (ref). DHP has also 
been associated with nausea and vomiting in about 1.6 – 6.9% of the treated patients [169]. In 
Rwanda, DHP administered among younger children (12-59 months) was also safe and 
tolerable [170]. Similar findings have been reported among Tanzanian children [171]. 
Therefore, increased vomiting observed may be due to the additional effect of DHP. However, 
adverse events following DHP alone administration were reported to be mild and transient, and 
no serious adverse events were reported [169]. Similar findings have been observed in this 
study, even in the presence of PZQ.  This study has demonstrated an early safety profile of the 
PZQ and DHP combination (within four hours of drug intake). We recommend future studies 
to assess safety for a much longer follow-up time. In a wide community MDA using PZQ and 
DHP combination therapy, an active cohort event monitoring should the deployed for safety 
monitoring.  
4.4 Effect of dihydroartemisinin-piperaquine on the pharmacokinetics of 
praziquantel (paper IV) 
A total of 64 Schistosoma mansoni infected children were included in this study, where 32 
participants were recruited in each treatment arm. Study participants were randomly selected 
from those who participated in the clinical trial (paper III). The overall mean age (±SD) of the 
studied population was 12.7±1.8 years. The overall median infection intensity (range) was 225 
(56-552). The infection intensity distribution was as follows; light infection 23 participants 
(35.8%), moderate infection 19 participants (29.7) and heavy infection 22 participants (34.4%). 
There was no significant difference for the baseline characteristics between the two treatment 
groups (p >0.05) (Table 1 - paper IV). 
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This study has found a significant drug-drug interaction between PZQ and DHP following their 
co-administration to treat schistosomiasis. The 90% CI of the geometric mean ratios of AUCs 
and Cmax of PZQ+DHP/PZQ for total PZQ, R-PZQ and S-PZQ were outside an acceptable 
bioequivalent interval of 0.80, 1.25. The geometric mean of AUCs and Cmax of total PZQ, R-
PZQ and S-PZQ were higher among children treated with PZQ and DHP combination than 
those treated with PZQ alone (Table 2, 3 & 4 – paper IV). These findings indicate that the 
systemic drug exposure of both PZQ and its enantiomers was increased by co-administration 
of DHP.  
Our findings is supported by a report by Lanusse C et al., 2018 on the strategies to optimize 
the efficacy of antihelminthic drugs, where pharmacokinetics optimization to enhance parasite 
exposure was reported [172]. PZQ and DHP combination produce drug-drug interactions 
which result in a synergistic effect and hence greater therapeutic efficacy than PZQ alone [78]. 
The bioavailability of a drug can be affected by drug-drug interactions through competitions 
for protein binding sites. Therefore, CYPs are a potent site of drug-drug interactions between 
drugs which share the same metabolic pathways or co-administration of CYPs inhibitors or 
inducers [78].  Induction or inhibition of the CYP450 enzymes can also result in drug-drug 
interactions of clinical significance, resulting in treatment success/failure or increased risk of 
adverse events [173]. Dihydroartemisinin is eliminated mainly by phase 2 metabolism, i.e. 
glucuronidation. Therefore, the observed drug-drug interaction between PZQ and DHP is most 
likely due to PZQ metabolism inhibition by piperaquine. Both PZQ and piperaquine undergo 
phase 1 metabolism via CYP450, primarily CYP3A4. Chloroquine, a 4- aminoquinoline 
similar to piperaquine [174], has been reported to inhibit PZQ metabolism [114]. Therefore, 
inhibition of PZQ metabolism by piperaquine resulted in increased AUCs and Cmax of PZQ. 
Higher total AUC of PZQ has been linked n increased parasitological cure [85]. The increased 
systemic PZQ exposure has also been reported when PZQ was administered with CYP450 
inhibitor i.e. ketoconazole [139]. However, DHP has more advantages than ketoconazole, 
including antischistosomal activity against juvenile worms and protection against malaria.  
Our results further support the reported high cure rates in a recent clinical trial where superior 
therapeutic efficacy was observed among children treated with PZQ and DHP combination 
[175]. The increased PZQ bioavailability in the PZQ and DHP combination therapy serves as 
an additional mechanism for enhancing the performance of PZQ apart from the killing of both 
mature and immature worms. Figure 7 summarizes factors affecting the activity of an 
antihelminthic drug. Therefore, the recommended PZQ and DHP combination therapy is 




Figure 7. Parasite and drug factors affecting the activity of the antihelminthic drugs. Source: 
Lanusse C et al., 2018 [172]. 
The findings from this pharmacokinetic study have opened room for further research in the 
field. The fact that the combination therapy increases PZQ systemic exposure, there is a chance 
to investigate the effectiveness of a low PZQ dose (< 40mg/kg) combined with DHP to treat 
schistosomiasis. This approach will reduce not only PZQ pills burden but also bitter taste. On 
the other hand, the prevalence of schistosomiasis in preschool children has been shown to 
correlate with that of school children in endemic countries [147]. In response to that, the WHO 
recommended PZQ treatment among preschool children after several studies reported that the 
drug is safe in this age group [149, 176].  However, pharmacokinetic studies have shown that 
AUCs of PZQ and its enantiomers in Schistosoma mansoni infected preschool children are 
higher than school-aged children [138]. In general, preschool children metabolize PZQ slowly 
[78]. Therefore, further studies are needed in preschool children to assess PZQ exposure and 
tolerability in PZQ and DHP combination therapy.  
4.5 Effect of pharmacogenetics variations on praziquantel plasma 
concentration and schistosomiasis treatment outcomes (paper V) 
A total of 340 study participants were enrolled in this study. Sub-study 5 was aimed to assess 
the impact of pharmacogenetics variation of PZQ on plasma drug concentrations and intestinal 
schistosomiasis treatment outcomes (efficacy and safety). The median age (range) of the study 
participants was 12 years (7-17). The median infection intensity (IQR) of the study population 
was 222 epg (96-468) (Table 1 – paper V). In this study, a pre-treatment whole blood sample 
(2 mL) was collected from 340 study participants for DNA isolation and genotyping. 
Genotyping for CYP3A4*1B, CYP3A5 (*3,*6,*7), CYP2C19 (*2,*3,*17) and CYP2C9 (*2,*3) 
alleles that are relevant for PZQ metabolism was done using Real-time PCR [111]. Plasma 
samples were collected at four hours post-PZQ administration from 287 study participants for 
quantification of PZQ and metabolite – trans-4-OH-PZQ concentrations. To the best of my 
knowledge, this is the first study to assess the effect of pharmacogenetics variations of PZQ on 
plasma drug concentrations and schistosomiasis treatment outcomes.  
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Our findings indicate that there was a significant association between CYP2C19 genotype and 
plasma PZQ concentration, and its metabolic ratio (trans-4-OH-PZQ/PZQ). PZQ concentration 
was significantly higher among children carrying CYP2C19 (*2, *3) alleles than the wild type 
(CYP2C19 *1/*1) and CYP2C19 *17 carriers (ultra-rapid metabolizers) (p = 0.04). The 
metabolic ratio was significantly higher among CYP2C19 *17 carriers than CYP2C19 (*2, *3) 
carriers (p = 0.01) (Table 3 – paper V). These findings indicate that CYP3A4/5 are not the 
major metabolic pathways for the formation of 4-OH-PZQ metabolite in humans. In fact, in 
vitro studies have reported CYP2C19 as a major metabolic pathway for the formation of 4-
OH-PZQ metabolite [177]. Similar findings have been reported recently where CYP3A4/5 
were reported to be involved in the formation of X-OH-PZQ metabolite and not 4-OH-PZQ 
[139].  
Our study found no significant impact of CYP3A4, CYP3A5, CYP2C19, and CYP2C9 
genotypes on schistosomiasis treatment efficacy at three weeks post-treatment (p > 0.05). 
Despite CYP3A4 being the major metabolizing enzyme for most drugs used to treat tropical 
infections, including PZQ, CYP3A4 genotype was not associated with schistosomiasis 
treatment efficacy (Table 4 – paper V). Although not statistically significant, those carrying 
CYP3A4 defective alleles i. e. CYP3A4*1B  were more cured than those with wild type 
genotype (CYP3A4*1/*1) (Table 4 and 5). This finding suggests a low CYP3A4 enzyme 
activity in those carrying CYP3A4 defective alleles. Similarly, children carrying CYP3A5 
defective alleles (*3, *6, *7) were more cured than the wild type (CYP3A5*1/*1) (p > 0.05) 
(Table 4 - paper V). CYP3A5 defective alleles (*3, *6, *7) are associated with reduced CYP3A5 
enzyme activity [115, 178]. Although CYP2C19 genotype significantly affect PZQ 
concentration and its metabolic ratio, CYP2C19 genotype was not significantly associated with 
schistosomiasis treatment efficacy. 
In this study, we observed no significant effect of CYP3A4, CYP2C19 and CYP2C9 genotypes 
on treatment-associated adverse events (p > 0.05).  However, a border line association was 
observed between CYP3A5 and adverse events (p = 0.048), where children carrying CYP3A5 
defective alleles (*3, *6, *7) had higher incidence of adverse events than the wild type 
(CYP3A5*1/*1). On multivariate logistic regression model, baseline infection intensity was 
found to be the only significant predictor of adverse events following PZQ treatment. Heavily 
infected children had significantly more incidence of adverse events compared to those with 
mild and moderate infections (p < 0.05) (Table 6 – paper V).  Our findings were contrary to 
reports from other infectious diseases such as HIV and Tuberculosis, where genetic variations 
in CYP450 were associated with adverse events [120, 121]. More pharmacogenetics studies of 
PZQ are needed to generate additional evidence in this field.
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5 CONCLUSIONS AND RECOMMENDATIONS 
Our findings contribute to the global strategies and efforts in the fight against neglected tropical 
diseases such as schistosomiasis. The most important conclusions and recommendations of the 
PhD research project in improving the treatment of schistosomiasis include the following:  
• The burden of intestinal schistosomiasis remains high despite ongoing interventions in the 
study area. We recommend regular assessment of the prevalence and infection intensity in 
affected areas for targeted implementation of preventive chemotherapy and other 
intervention measures by the National NTDs Control Program. The surveillance of 
schistosomiasis prevalence should not only focus on school children but also involve other 
key populations such as pre-school children. 
 
• Single-dose praziquantel is safe and efficacious against Schistosoma mansoni infection. 
However, lack of cure in about 18% of the treated children points to the need for treatment 
optimization research. We also recommend regular monitoring of the efficacy of 
praziquantel for early detection of reduced efficacy or drug resistance would be critical to 
ensure control and prevention of schistosomiasis in high burden settings. 
  
• Praziquantel and dihydroartemisinin-piperaquine combination therapy have superior 
efficacy than praziquantel alone for the treatment of schistosomiasis. The combination 
therapy is equally safe to praziquantel alone when used to treat schistosomiasis among 
school children. We recommend the adoption of this combination therapy for the treatment 
and control of schistosomiasis in endemic countries. Since schistosomiasis control and 
elimination is multifactorial, the use of the praziquantel and dihydroartemisinin-
piperaquine combination therapy should be coupled to other control strategies, including 
supply of safe and clean water and improvement in sanitation and hygiene. Future studies 
to assess the acceptability, feasibility and cost-effectiveness of this combination therapy is 
recommended. 
 
• Dihydroartemisinin-piperaquine increases the systemic exposure of praziquantel and hence 
its therapeutic efficacy. The increased systemic praziquantel exposure is an additional 
mechanism by which the therapeutic efficacy of the combination therapy increased, apart 
from killing both immature and mature stages of the parasite. Since the same combination 
therapy could be similarly beneficial to pre-school children, we recommend studies to 
assess the tolerability of combination therapy in this age group. This is because in previous 
studies, pre-school has been shown to have higher AUC compared to school children due 
to slow metabolism. 
 
• CYP2C19 genotype significantly affects praziquantel concentration and metabolic ratio 
(trans-4-OH-praziquantel/praziquantel) following praziquantel treatment. No significant 
effect of CYP3A4, CYP2C19, and CYP2C9 genotypes on schistosomiasis treatment 
efficacy and adverse events was observed. However, a border line association between 
CYP3A5 genotype and adverse events was observed. Future pharmacogenetics studies 
should consider evaluating the impact of CYP1A2 and CYP2D6 genotypes on plasma drug 
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